β3-Adrenoceptor antagonism improves clinical outcomes of chronic heart failure

Medical Hypotheses

Volumn 69, Issue 5, 2007, Pages 1114-1116

  Wu, Tongguo ^a   Wang, Lexin ^b  

^a GUANGZHOU RED CROSS HOSPITAL   (China)

^b CHARLES STURT UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 3 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; L 748337; METOPROLOL; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFECT; GENE OVEREXPRESSION; HEART FAILURE; HEART VENTRICLE CONTRACTILITY; HEART VENTRICLE FUNCTION; HOSPITALIZATION; HUMAN; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SURVIVAL; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CARDIAC OUTPUT, LOW; HEART; HUMANS; MODELS, CARDIOVASCULAR; MYOCARDIUM; RECEPTORS, ADRENERGIC, BETA-3; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

ANIMALIA;

EID: 34548756049     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.10.068     Document Type: Article

References (15)

1. Cowie M.R., Mosterd A., Wood D.A., et al. The epidemiology of heart failure. Eur Heart J 18 (1997) 208-225
2. Khand A., Gemmel I., Clark A.L., and Cleland J.G.F. Is the prognosis of heart failure improving?. J Am Coll Cardiol 36 (2000) 2284-2286
3. Hasking G.J., Esler M.D., Jennings G.L., Burton D., and Korner P.I. Norepinephrine spillover to plasma in patients with chronic congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 73 (1986) 615-621
4. Bristow M.R. β-Adrenergic receptor blockade in chronic heart failure. Circulation 101 (2000) 558
5. Gauthier C., Tavernier G., Charpentier F., et al. Functional β3-adrenoceptor in the human heart. J Clin Invest 98 (1996) 556-562
6. Gauthier C., Leblais V., Kobzik L., et al. The negative inotropic effect of β3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J Clin Invest 102 (1998) 1377-1384
7. 3-adrenergic receptor in the failing canine myocardium. Circ Res 89 (2001) 599-606
8. 3-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation 103 (2001) 1649-1655
9. 1-receptor downregulation in heart failure. Circ Res 59 (1986) 297-309
10. Mann D.L., Kent R.L., Parsons B., and Cooper G.I.V. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 85 (1992) 790-804
11. 3-adrenoceptors in rat hearts. Diabetes 50 (2001) 455-461
12. 3-adrenergic stimulation in the human heart: signal transduction, functional implications and therapeutic perspectives. Pharmizie 61 (2006) 255-260
13. Poole-Wilson P.A., Swedberg K., Cleland J.G., et al. Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol european trial (COMET). Lancet 362 (2003) 7-13
14. Hoffmann C., Leitz M.R., Oberdorf-Maass S., Lohse M.J., and Klotz K.N.K. Comparative pharmacology of human β-adrenergic receptor subtypes - characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 369 (2004) 151-159
15. 3-adrenoreceptor activation contributes to the left ventricular and cardiomyocyte dysfunction in heart failure. Am J Physiol Heart Circ Physiol 286 (2004) H2425-H2433